Search clinical trials for: SAR425899

Total 9 results

Sanofi

Completed

A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects

Type 2 Diabetes Mellitus

United States
Sanofi

Completed

A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period

Type 2 Diabetes Mellitus

United States
Sanofi

Withdrawn

Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease (Restore)

Type 2 Diabetes Mellitus | Non-alcoholic Steatohepatitis
Sanofi

Terminated

Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B

Retinitis Pigmentosa | Usher Syndrome

United States, France
Sanofi

Completed

Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients

Type 2 Diabetes Mellitus

Germany
Sanofi

Completed

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany, Spain, United States, Canada, Czechia, Hungary, Mexico, Russian Federation
Sanofi

Completed

SAR407899 Single-dose in Treatment of Mild to Moderate Erectile Dysfunction (RHOKET)

Erectile Dysfunction

France
Sanofi
Antaros Medical

Completed

A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

Sweden
Sanofi

Terminated

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

Microvascular Coronary Artery Disease

United States, Denmark, Korea, Republic of, Netherlands, Sweden

3

Subscribe